TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.
The user experienced new hair growth after switching from oral finasteride to topical RU58841 with minoxidil and undergoing stem cell therapy. They noticed new hairs at the hairline and temples, but are unsure which treatment is responsible.
Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.
The user experienced hair regrowth using 0.5mg oral finasteride and the iRestore laser cap every other day, with reduced shedding. They also take collagen peptides and Nutrafol vitamins, though they are unsure of the latter's effectiveness.
A South Korean company, Therazyne, has developed a promising hair loss treatment using a WNT chain surrogate that binds to Frizzled 7, with human follicle testing expected soon. Current treatments like minoxidil and finasteride are not seen as cures, and while optimism exists for future solutions like PP405, approval processes are lengthy.
Glycine supplementation may increase 5-alpha reductase activity, potentially affecting hair loss. Users discuss its impact on hair fall and its role in the body.
GT20029 showed promising results for hair growth in a Phase II trial, with the 1.0% twice-weekly regimen being the most effective. Some users expressed skepticism and humor about the product's effects and market availability.
A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.
Rhamnose may promote hair growth and pigmentation, suggesting it as a potential hair loss treatment. The conversation discusses its potential alongside known treatments like Minoxidil, finasteride, and RU58841.
Setipiprant and bimatoprost are being discussed as potential future treatments for hair loss. Some individuals have started testing setipiprant before FDA approval, but no progress updates are available yet.
A sugar gel containing 2-deoxy-D-ribose has shown promising hair regrowth results in mice, comparable to Minoxidil. Users are discussing the potential to buy and try this compound themselves.
A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.
Lab-grown hair using iPSCs is being explored, but practical applications are limited. Finasteride is suggested as the only current effective treatment.
Scientists have grown natural-looking hair from stem cells, potentially revolutionizing hair growth treatments. Concerns include cost, DHT resistance, and the need for future procedures.
The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.
The conversation discusses using microneedling with growthfactor serum, PRF injections, dutasteride, oral and topical minoxidil, and topical exosomes to treat hair loss, particularly on the crown. OP plans to microneedle twice a month and seeks feedback on Korean growthfactor serums.
The conversation is about using inositol for hair loss, particularly its potential benefits for men, given its success in women with PCOS. The discussion includes treatments like Minoxidil, finasteride, and RU58841.
The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.
HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.
The conversation is about the difficulty in obtaining GT20029, a hair loss treatment, due to patent issues and the need to resort to group buys or Chinese labs for acquisition. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
Mango oil may inhibit DKK1 and DHT, potentially aiding hair growth by activating the Wnt signaling pathway. A user plans to test mango leaves juice and other Ayurvedic products for hair regrowth.
Panax ginseng, specifically a ginsenoside-enriched formulation, is suggested as a potential hair growth treatment alongside finasteride and minoxidil. The user is considering trying panax ginseng despite limited availability and evidence.
Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.
Maneup GHK-Cu peptide was used for hair loss, resulting in some hair growth in the receded hairline, but the new hairs were dry and split easily. Users discussed their experiences with this treatment.
Hair loss therapies focusing on hair follicle sugar metabolism and aldose reductase. Potential treatments include magnesium supplements, avoiding high glycemic index foods, and antioxidants.
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
The potential of lowering prolactin levels to regrow hair, with a reference to Bayer's drug HMI 115 which has been indicated as having this effect. Treatments mentioned include Minoxidil and Finasteride, as well as RU58841.